In tumor-bearing mice, excess unlabeled exendin‑4 markedly reduced radiolabeled exendin‑4 conjugate tumor uptake.
In plain wordsIn mice with tumors, excess unlabeled exendin‑4 markedly reduced tumor uptake of the labeled probe.
- Peptide
- Exenatide (exendin-4)
- Outcome
- DecreaseTumor tracer uptake blockade
- Study
mousen: not reported in source
INS-1 tumor and islet transplantation models- Comparator
- radiotracer without excess unlabeled exendin-4
- Outcome group
- Receptor activity and mechanism · Pharmacology
Source sentences
Tumor uptake was saturable, reduced dramatically by a 20-fold excess of unlabeled Exendin-4.
1 context sentence(design, population, supporting numbers)
After (64)Cu labeling, biodistribution studies and microPET imaging of (64)Cu-DO3A-VS-Cys(40)-Exendin-4 were performed on both subcutaneous INS-1 tumors and islet transplantation models.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).